PENTAX Medical launches the C2 CryoBalloon™ Ablation System in Canada for the treatment of Barrett’s Esophagus
Mississauga, ON – October 5th, 2022 – PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today the Canadian launch of the C2 CryoBalloon™ Ablation System for the treatment of Barrett’s Esophagus.
“With the launch of C2 CryoBalloon Ablation System, there is now a new and effective way to treat Barrett’s Esophagus in Canada”, says PENTAX Medical Americas, Chief Commercial Officer, David Harrison.
The estimated prevalence of Barrett’s Esophagus in the Canadian population varies between 2% and 7%,and approximately 0.5% of people with Barret’s Esophagus develop esophageal cancer1,2. The C2 CryoBalloon Ablation System has been shown to be a highly effective therapy for the treatment of Barrett’s Esophagus. Patients experience lower peak pain from CryoBalloon treatment vs conventional Radio Frequency Ablation (RFA) and the duration of pain is reduced by 50% (2 days for CryoBalloon treatment vs 4 days for RFA). Additionally, CryoBalloon patients used analgesics for a shorter duration as compared to RFA (2 days vs 4 days for RFA)3,4,5.
TheC2 CryoBalloon Ablation System provides significant economic advantage to hospitals, with minimal capital investment, as compared to contemporary RFA systems3. Clinicians also experience enhanced visualization and control, thanks to the versatile through-the-scope balloon catheter technology. Patients benefit from controlled delivery and depth of ablation therapy that reduces tissue trauma. Scholvinck states “Cryotherapy is minimally destructive to the structural components of tissue such as collagen, whereas heat-based ablation techniques irreversibly destroy proteins, thereby affecting the architecture of the collagen matrix4.
“By introducing the only CryoBalloon Ablation system for Barrett’s Esophagus into the Canadian market, PENTAX Medical follows its mission to improve the standard of patient care and enhance patients’ and providers’ experience”, says Harrison. “We are excited about launching the C2 CryoBalloon Ablation System and the benefits it provides to patients. Studies show that patients experience less post-procedure pain, and CryoBalloon ablation is proven to preserve the esophageal tissue's extracellular matrix, as compared to RFA. to the patient’s tissue as compared to RFA. We are pleased to introduce this new, innovative technology to assist with the treatment of Canadians suffering from Barrett’s Esophagus.”
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community’s Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations. For more information: www.pentaxmedical.com.
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA’s divisions and business units research and develop products utilized in the healthcare and information technology fields. In the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes, contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device reprocessing and disinfection solutions. In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries. With over 160 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 38,000 people. For more information, please visit www.hoya.com.
1.Macías-García F and Domínguez-Muñoz JE. Update on management of Barrett’s esophagus. World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):227-34.
2. Canadian Cancer Society. 2018. Esophageal cancer – Precancerous conditions of the esophagus.
3.Canto MI, Shahhen NJ, Almario JA, Voltaggio L, Montgomery E, Lightdale CJ. Multifocal nitrous oxide C2 CryoBalloon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus. Gastrointestinal Endoscopy Volume 88, No. 3 2018
4.Scholvinck DW, Kunzli HT, Kestens C, Siersema PD, Vleggaar FP, Canto MI, Cosby H, Abrams JA, Lightdale CJ, Tejeda-Ramirez E, DeMeester SR, Greene CL, Jobe BA, Peters J, Bergman J, Weusten B Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy. 2015 Dec: 47 (12) 1106-1112.
5. Van Munster SN, Overwater A, Haidry R, Bisschops R, Bergamn J, Weusten BL. Focal cryoBalloon verses radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Clinical Endoscopy.
